Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"LTS - Lohmann Therapie Systeme","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LTS and LIVZON Enter into License and Collaboration Agreement to Develop and Commercialize Asenapine TTS","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Bright Peak Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bright Peak Therapeutics Licenses Rights to Livzon\u2019s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Onconic Therapeutics","pharmaFlowCategory":"D","amount":"$127.5 million","upfrontCash":"$15.0 million","newsHeadline":"Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Livzon Pharmaceutical Group

    Menu

    Livzon Pharmaceutical Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Livzon Pharmaceutical Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million

              Details:

              Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan, Hong Kong and Macau.

              Lead Product(s): Zastaprazan

              Therapeutic Area: Gastroenterology Product Name: JP 1366

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Onconic Therapeutics

              Deal Size: $127.5 million Upfront Cash: $15.0 million

              Deal Type: Acquisition March 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Livzon Pharmaceutical Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines

              Details:

              Under the terms of the license agreement, Bright Peak will receive the right to develop, manufacture and commercialize PD-1 ICs, including LZM009 on a worldwide basis while Livzon retains certain rights of first negotiation to obtain exclusivity in the greater China territory.

              Lead Product(s): LZM009

              Therapeutic Area: Oncology Product Name: LZM009

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Bright Peak Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Livzon Pharmaceutical Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LTS and LIVZON Enter into License and Collaboration Agreement to Develop and Commercialize Asenapine TTS

              Details:

              LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).

              Lead Product(s): Asenapine Maleate

              Therapeutic Area: Psychiatry/Psychology Product Name: Asenapine TTS

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: LTS - Lohmann Therapie Systeme

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY